Symbols / APGE Stock $85.61 -3.04% Apogee Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
APGE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Michael Thomas Henderson M.D.
Exch · Country NGM · United States
Market Cap 6.39B
Enterprise Value 5.36B
Income -255.84M
Sales —
FCF (ttm) -138.98M
Book/sh 13.21
Cash/sh 10.61
Employees 261
Insider 10d —
IPO Jul 14, 2023
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout —
P/E —
Forward P/E -15.68
PEG —
P/S —
P/B 6.48
P/C —
EV/EBITDA -18.85
EV/Sales —
Quick Ratio 26.38
Current Ratio 26.57
Debt/Eq 0.98
LT Debt/Eq —
EPS (ttm) -4.22
EPS next Y -5.46
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-03-02
ROA -21.11%
ROE -31.57%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 61.11M
Shs Float 52.92M
Insider Own 5.44%
Instit Own 127.73%
Short Float 22.28%
Short Ratio 7.44
Short Interest 9.73M
52W High 95.31
vs 52W High -10.18%
52W Low 34.34
vs 52W Low 149.30%
Beta 1.02
Impl. Vol. 59.52%
Rel Volume 0.53
Avg Volume 970.22K
Volume 514.38K
Target (mean) $116.87
Tgt Median $118.00
Tgt Low $82.00
Tgt High $160.00
# Analysts 15
Recom Strong_buy
Prev Close $88.29
Price $85.61
Change -3.04%
About

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$116.87
Mean price target
2. Current target
$85.61
Latest analyst target
3. DCF / Fair value
$-40.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$85.61
Low
$82.00
High
$160.00
Mean
$116.87

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-30 main Mizuho Outperform → Outperform $110
2026-03-24 main Citigroup Buy → Buy $125
2026-03-24 main Canaccord Genuity Buy → Buy $130
2026-03-24 main Guggenheim Buy → Buy $160
2026-03-23 reit BTIG Buy → Buy $137
2026-03-18 init Truist Securities — → Hold $83
2026-03-16 reit BTIG Buy → Buy $137
2026-03-03 main RBC Capital Sector Perform → Sector Perform $82
2026-03-03 main Wedbush Outperform → Outperform $95
2026-01-22 down RBC Capital Outperform → Sector Perform $83
2026-01-07 init Wolfe Research — → Peer Perform —
2026-01-06 main BTIG Buy → Buy $137
2026-01-05 main BTIG Buy → Buy $128
2025-12-17 init Stephens & Co. — → Overweight $95
2025-12-10 init Deutsche Bank — → Buy $103
2025-11-03 init Craig-Hallum — → Buy $109
2025-11-03 main RBC Capital Outperform → Outperform $70
2025-10-21 init Mizuho — → Outperform $105
2025-10-09 reit BTIG Buy → Buy $115
2025-09-25 init RBC Capital — → Outperform $60
News
RSS: Latest APGE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-16 HENDERSON JANE Chief Financial Officer — 2,000 $90.00 $180,000
2026-04-16 HENDERSON MICHAEL THOMAS Chief Executive Officer — 3,000 $22.86 $68,580
2026-04-08 HENDERSON MICHAEL THOMAS Chief Executive Officer — 20,000 $82.48 $1,651,664
2026-04-01 HENDERSON JANE Chief Financial Officer — 2,000 $84.46 $170,020
2026-04-01 DAMBKOWSKI CARL Officer — 5,500 $84.31 $466,619
2026-04-01 DAMBKOWSKI CARL Officer — 4,125 $22.86 $94,298
2026-03-25 HENDERSON JANE Chief Financial Officer — 2,000 $85.00 $170,000
2026-03-11 HENDERSON MICHAEL THOMAS Chief Executive Officer — 20,000 $74.29 $1,495,605
2026-03-04 DAMBKOWSKI CARL Officer — 5,500 $70.33 $390,825
2026-03-04 DAMBKOWSKI CARL Officer — 4,125 $22.86 $94,298
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
285.60
+31.69%
216.87
+133.19%
93.00
+202.68%
30.73
Research And Development
214.71
+27.91%
167.87
+145.33%
68.42
+146.25%
27.79
Selling General And Administration
69.75
+42.34%
49.01
+99.38%
24.58
+735.74%
2.94
General And Administrative Expense
69.75
+42.34%
49.01
+99.38%
24.58
+735.74%
2.94
Salaries And Wages
50.64
+67.10%
30.30
+140.94%
12.58
+665.96%
1.64
Other Gand A
19.12
+2.22%
18.70
-23.91%
24.58
+1792.15%
1.30
Total Expenses
285.60
+31.69%
216.87
+133.19%
93.00
+202.68%
30.73
Operating Income
-285.60
-31.69%
-216.87
-133.19%
-93.00
-202.68%
-30.73
Total Operating Income As Reported
-285.60
-31.69%
-216.87
-133.19%
-93.00
-202.68%
-30.73
EBITDA
-284.18
-31.15%
-216.68
-132.98%
-93.00
-203.58%
-30.64
Normalized EBITDA
-284.18
-31.15%
-216.68
-132.98%
-93.00
-203.58%
-30.64
Reconciled Depreciation
1.42
+650.26%
0.19
0.00
—
EBIT
-285.60
-31.69%
-216.87
-133.19%
-93.00
-203.58%
-30.64
Net Income
-255.84
-40.46%
-182.15
-116.88%
-83.98
-111.10%
-39.78
Pretax Income
-255.56
-40.32%
-182.13
-116.86%
-83.98
-111.10%
-39.78
Net Non Operating Interest Income Expense
30.03
-13.56%
34.74
+285.25%
9.02
+199.56%
-9.06
Interest Expense Non Operating
—
—
0.00
-100.00%
9.15
Net Interest Income
30.03
-13.56%
34.74
+285.25%
9.02
+199.56%
-9.06
Interest Expense
—
—
0.00
-100.00%
9.15
Interest Income Non Operating
30.03
-13.56%
34.74
+285.25%
9.02
+9702.17%
0.09
Interest Income
30.03
-13.56%
34.74
+285.25%
9.02
+9702.17%
0.09
Tax Provision
0.28
+1444.44%
0.02
0.00
—
Tax Rate For Calcs
0.00
+0.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-255.84
-40.46%
-182.15
-116.88%
-83.98
-111.10%
-39.78
Net Income From Continuing Operation Net Minority Interest
-255.84
-40.46%
-182.15
-116.88%
-83.98
-111.10%
-39.78
Net Income From Continuing And Discontinued Operation
-255.84
-40.46%
-182.15
-116.88%
-83.98
-111.10%
-39.78
Net Income Continuous Operations
-255.84
-40.46%
-182.15
-116.88%
-83.98
-111.10%
-39.78
Normalized Income
-255.84
-40.46%
-182.15
-116.88%
-83.98
-111.10%
-39.78
Net Income Common Stockholders
-255.84
-40.46%
-182.15
-116.88%
-83.98
-111.10%
-39.78
Diluted EPS
—
-3.30
+1.79%
-3.36
-130.11%
-1.46
Basic EPS
—
-3.30
+1.79%
-3.36
-130.11%
-1.46
Basic Average Shares
—
55.19
+120.72%
25.01
-8.22%
27.25
Diluted Average Shares
—
55.19
+120.72%
25.01
-8.22%
27.25
Diluted NI Availto Com Stockholders
-255.84
-40.46%
-182.15
-116.88%
-83.98
-111.10%
-39.78
Depreciation Amortization Depletion Income Statement
1.13
0.00
—
—
Depreciation And Amortization In Income Statement
1.13
0.00
—
—
Depreciation Income Statement
1.13
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
937.13
+24.30%
753.95
+87.83%
401.40
+163.99%
152.06
Current Assets
741.36
+39.95%
529.71
+32.96%
398.41
+162.02%
152.06
Cash Cash Equivalents And Short Term Investments
730.19
+40.25%
520.65
+31.66%
395.46
+160.36%
151.89
Cash And Cash Equivalents
131.55
-7.22%
141.79
+19.84%
118.32
-22.10%
151.89
Cash Financial
—
—
—
151.89
Other Short Term Investments
598.64
+58.01%
378.86
+36.70%
277.14
0.00
Receivables
5.96
+26.91%
4.70
+286.90%
1.21
—
Accrued Interest Receivable
5.96
+26.91%
4.70
+286.90%
1.21
—
Prepaid Assets
4.60
+75.51%
2.62
+50.98%
1.74
+1507.41%
0.11
Other Current Assets
0.60
-65.27%
1.74
+43.49%
1.21
+2029.82%
0.06
Total Non Current Assets
195.78
-12.69%
224.24
+7387.08%
3.00
0.00
Net PPE
14.38
+7.89%
13.32
+413.65%
2.59
0.00
Gross PPE
15.98
+18.28%
13.51
+420.93%
2.59
0.00
Accumulated Depreciation
-1.61
-750.79%
-0.19
0.00
—
Properties
0.00
0.00
0.00
—
Machinery Furniture Equipment
2.75
0.00
—
—
Other Properties
10.16
-19.72%
12.65
+387.66%
2.59
—
Leases
3.08
+256.32%
0.86
0.00
—
Investments And Advances
172.73
-17.91%
210.42
0.00
—
Other Non Current Assets
8.67
+1641.16%
0.50
+24.19%
0.40
—
Total Liabilities Net Minority Interest
33.25
-10.51%
37.16
+72.90%
21.49
+115.34%
9.98
Current Liabilities
27.91
-2.29%
28.56
+38.92%
20.56
+105.99%
9.98
Payables And Accrued Expenses
20.74
-11.47%
23.43
+21.47%
19.29
+103.80%
9.46
Payables
1.22
+14.01%
1.07
-50.02%
2.14
+412.68%
0.42
Accounts Payable
1.22
+14.01%
1.07
-50.02%
2.14
+412.68%
0.42
Current Accrued Expenses
19.52
-12.69%
22.36
+30.40%
17.15
+89.53%
9.05
Pensionand Other Post Retirement Benefit Plans Current
3.66
+93.03%
1.90
+1034.73%
0.17
-67.57%
0.52
Current Debt And Capital Lease Obligation
3.50
+8.35%
3.23
+193.73%
1.10
—
Current Capital Lease Obligation
3.50
+8.35%
3.23
+193.73%
1.10
0.00
Total Non Current Liabilities Net Minority Interest
5.34
-37.83%
8.60
+821.44%
0.93
0.00
Long Term Debt And Capital Lease Obligation
5.34
-37.83%
8.60
+821.44%
0.93
0.00
Long Term Capital Lease Obligation
5.34
-37.83%
8.60
+821.44%
0.93
0.00
Stockholders Equity
903.88
+26.10%
716.79
+88.67%
379.91
0.00
Common Stock Equity
903.88
+26.10%
716.79
+88.67%
379.91
0.00
Capital Stock
0.00
+0.00%
0.00
0.00
0.00
Common Stock
0.00
+0.00%
0.00
0.00
0.00
Preferred Stock
—
0.00
0.00
0.00
Share Issued
68.40
+15.00%
59.48
+22.59%
48.52
+1.04%
48.02
Ordinary Shares Number
68.40
+15.00%
59.48
+22.59%
48.52
+1.04%
48.02
Additional Paid In Capital
1,464.56
+43.33%
1,021.79
+103.00%
503.35
0.00
Retained Earnings
-561.76
-83.63%
-305.92
-147.16%
-123.77
-211.10%
-39.78
Gains Losses Not Affecting Retained Earnings
1.08
+18.03%
0.92
+178.12%
0.33
0.00
Other Equity Adjustments
1.08
+18.03%
0.92
+178.12%
0.33
—
Total Equity Gross Minority Interest
903.88
+26.10%
716.79
+88.67%
379.91
+167.40%
142.07
Total Capitalization
903.88
+26.10%
716.79
+88.67%
379.91
+167.40%
142.07
Working Capital
713.45
+42.36%
501.15
+32.63%
377.85
+165.95%
142.07
Invested Capital
903.88
+26.10%
716.79
+88.67%
379.91
0.00
Total Debt
8.85
-25.20%
11.83
+481.66%
2.03
0.00
Capital Lease Obligations
8.85
-25.20%
11.83
+481.66%
2.03
0.00
Net Tangible Assets
903.88
+26.10%
716.79
+88.67%
379.91
0.00
Tangible Book Value
903.88
+26.10%
716.79
+88.67%
379.91
0.00
Available For Sale Securities
172.73
-17.91%
210.42
—
—
General Partnership Capital
—
—
—
2.14
Investmentin Financial Assets
172.73
-17.91%
210.42
0.00
—
Limited Partnership Capital
—
0.00
0.00
-100.00%
181.86
Total Partnership Capital
—
-305.00
-147.08%
-123.44
-186.88%
142.07
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-227.45
-32.88%
-171.17
-128.96%
-74.76
-355.11%
-16.43
Cash Flow From Continuing Operating Activities
-227.45
-32.88%
-171.17
-128.96%
-74.76
-355.11%
-16.43
Net Income From Continuing Operations
-255.84
-40.46%
-182.15
-116.88%
-83.98
-111.10%
-39.78
Depreciation Amortization Depletion
1.42
+650.26%
0.19
0.00
—
Depreciation
1.42
+650.26%
0.19
0.00
—
Depreciation And Amortization
1.42
+650.26%
0.19
0.00
—
Other Non Cash Items
3.68
+117.06%
1.69
+1847.13%
0.09
-99.24%
11.40
Stock Based Compensation
46.28
+98.34%
23.33
+282.30%
6.10
+184.92%
2.14
Change In Working Capital
-15.48
-673.13%
-2.00
-132.79%
6.11
-37.80%
9.81
Change In Prepaid Assets
-2.11
+65.36%
-6.08
-118.31%
-2.79
-1587.88%
-0.17
Change In Payables And Accrued Expense
-0.92
-117.70%
5.22
-43.67%
9.27
-7.14%
9.98
Change In Accrued Expense
-1.07
-117.07%
6.29
-17.79%
7.65
-19.95%
9.56
Change In Payable
0.15
+113.99%
-1.07
-166.46%
1.61
+285.89%
0.42
Change In Account Payable
0.15
+113.99%
-1.07
-166.46%
1.61
+285.89%
0.42
Change In Other Current Assets
-8.47
-8628.87%
-0.10
+9.35%
-0.11
0.00
Change In Other Current Liabilities
-3.98
-280.96%
-1.04
-287.04%
-0.27
0.00
Investing Cash Flow
-179.57
+40.23%
-300.46
-9.69%
-273.91
0.00
Cash Flow From Continuing Investing Activities
-179.57
+40.23%
-300.46
-9.69%
-273.91
0.00
Net PPE Purchase And Sale
-5.15
-346.79%
-1.15
-589.82%
-0.17
0.00
Purchase Of PPE
-5.15
-346.79%
-1.15
-589.82%
-0.17
0.00
Capital Expenditure
-5.15
-346.79%
-1.15
-589.82%
-0.17
—
Net Investment Purchase And Sale
-174.43
+41.72%
-299.31
-9.34%
-273.74
0.00
Purchase Of Investment
-642.30
+1.10%
-649.45
-113.82%
-303.74
0.00
Sale Of Investment
467.87
+33.62%
350.14
+1067.13%
30.00
0.00
Financing Cash Flow
396.49
-19.92%
495.11
+56.98%
315.39
+87.38%
168.32
Cash Flow From Continuing Financing Activities
396.49
-19.92%
495.11
+56.98%
315.39
+87.38%
168.32
Net Common Stock Issuance
389.63
-21.04%
493.48
+56.47%
315.39
0.00
Proceeds From Stock Option Exercised
6.86
+321.65%
1.63
0.00
—
Changes In Cash
-10.53
-144.88%
23.47
+170.53%
-33.28
-121.91%
151.89
Beginning Cash Position
142.08
+19.79%
118.61
-21.91%
151.89
0.00
End Cash Position
131.55
-7.41%
142.08
+19.79%
118.61
-21.91%
151.89
Free Cash Flow
-232.60
-34.97%
-172.33
-129.99%
-74.93
-356.13%
-16.43
Amortization Of Securities
-7.50
+38.72%
-12.24
-298.60%
-3.07
0.00
Common Stock Issuance
389.63
-21.04%
493.48
+56.47%
315.39
0.00
Issuance Of Capital Stock
389.63
-21.04%
493.48
+56.47%
315.39
+87.38%
168.32
Net Preferred Stock Issuance
—
—
0.00
-100.00%
168.32
Preferred Stock Issuance
—
—
0.00
-100.00%
168.32
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category